Literature DB >> 21400978

Optimal choice of acetylcholinesterase reactivators for antidotal treatment of nerve agent intoxication.

Jirí Bajgar1.   

Abstract

The studies dealing with mechanism of organophosphates (OP)/nerve agent action, prophylaxis and treatment of intoxications is a very hot topic at present. Though the research is very intensive, unfortunately, up to now, there is not universal or significantly better reactivator sufficiently effective against all nerve agents/OP when compared with presently available oximes (pralidoxime, methoxime, obidoxime, trimedoxime, HI-6). The use of the most effective reactivator (HI-6) using simple type of autoinjector (e.g. ComboPen) is strictly limited because of decomposition of HI-6 in solution. Thanks to better solubility it is clear that another salt of HI-6 (dimethanesulfonate, HI-6 DMS) is more convenient for the use as antidote against nerve agents in the autoinjector than HI-6 chloride (Cl). It was clearly demonstrated that reactivation potency of HI-6 DMS in comparison with HI-6 Cl in vivo was the same and bioavailability of HI-6 DMS is better than that of HI-6 Cl. Three chambered autoinjector allows administration of all three antidotes (atropine, reactivator, diazepam) simultaneously. Moreover, the content of chambers can be changed according to proposed requirements. Possible way to solve the problem of universal reactivator could be the use of two reactivators. Three chambered autoinjector is an ideal device for this purpose.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21400978     DOI: 10.14712/18059694.2016.78

Source DB:  PubMed          Journal:  Acta Medica (Hradec Kralove)        ISSN: 1211-4286


  7 in total

1.  A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.

Authors:  Steven L Miller; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Camila P Almeida-Suhett; James P Apland; Maria F M Braga
Journal:  Toxicol Appl Pharmacol       Date:  2015-02-15       Impact factor: 4.219

2.  A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides.

Authors:  Christina M Wilhelm; Thomas H Snider; Michael C Babin; David A Jett; Gennady E Platoff; David T Yeung
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-31       Impact factor: 4.219

3.  Pharmacokinetics of three novel pyridinium aldoxime acetylcholinesterase reactivators in female rats.

Authors:  Brian S Backer; Edward C Meek; Matthew K Ross; Janice E Chambers
Journal:  Toxicol Appl Pharmacol       Date:  2022-05-10       Impact factor: 4.460

4.  A rodent model of human organophosphate exposure producing status epilepticus and neuropathology.

Authors:  W Pouliot; S L Bealer; B Roach; F E Dudek
Journal:  Neurotoxicology       Date:  2016-08-12       Impact factor: 4.294

5.  Antiseizure and neuroprotective effects of delayed treatment with midazolam in a rodent model of organophosphate exposure.

Authors:  Jay Spampanato; Wendy Pouliot; Steven L Bealer; Bonnie Roach; Francis Edward Dudek
Journal:  Epilepsia       Date:  2019-05-24       Impact factor: 6.740

Review 6.  Autoinjector device for rapid administration of drugs and antidotes in emergency situations and in mass casualty management.

Authors:  Rajagopalan Vijayaraghavan
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Acetylcholinesterase reactivators (HI-6, obidoxime, trimedoxime, K027, K075, K127, K203, K282): structural evaluation of human serum albumin binding and absorption kinetics.

Authors:  Filip Zemek; Jana Karasova Zdarova; Vendula Sepsova; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2013-08-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.